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Caloric restriction (CR) is a dietary regimen known to promote lifespan by slowing down the occurrence of age-dependent diseases. The
greatest risk factor for neurodegeneration in the brain is age, from which follows that CR might also attenuate the progressive loss of
neurons that is often associated with impaired cognitive capacities. In this study, we used a transgenic mouse model that allows for a
temporally andspatially controlledonset ofneurodegeneration to test thepotentially beneficial effects ofCR.We found that in thismodel,
CR significantly delayed the onset of neurodegeneration and synaptic loss and dysfunction, and thereby preserved cognitive capacities.
Mechanistically, CR induced the expression of the known lifespan-regulating protein SIRT1, prompting us to test whether a pharmaco-
logical activation of SIRT1 might recapitulate CR. We found that oral administration of a SIRT1-activating compound essentially repli-
cated the beneficial effects of CR. Thus, SIRT1-activating compounds might provide a pharmacological alternative to the regimen of CR
against neurodegeneration and its associated ailments.
Introduction
Caloric restriction (CR), the reduction in the consumption of
calories, is an effective regimen to slow aging in a variety of or-
ganisms ranging from yeast, nematodes, and fruitflies to mam-
mals (Bishop and Guarente, 2007; Fontana et al., 2010). CR acts
on a broad spectrum of tissues including liver, muscle, fat, pan-
creatic -cells, and, interestingly, also the brain (Bordone and
Guarente, 2005, 2007). There, CR has been shown to lead to an
attenuation of age-associated ailments, in particular, Alzheimer’s
disease (AD)-related pathologies: CR reduced the load of
amyloid-, a pathological hallmark of AD, in different mouse
models of AD (Patel et al., 2005; Wang et al., 2005; Qin et al.,
2006b, Halagappa et al., 2007; Wu et al., 2008b; Mouton et al.,
2009) and in aged squirrel monkeys (Qin et al., 2006a), and in the
3xTg ADmouse model, CR also reduced the phosphorylation of
tau (Halagappa et al., 2007), another pathological aggregation in
AD. Furthermore, CR was shown to rescue against memory def-
icits in several of these models (Halagappa et al., 2007; Wu et al.,
2008b), and similar effects were also observed in wild-type mice
(Fonta´n-Lozano et al., 2007) and in aged humans (Witte et al.,
2009). Last, in an endpoint study with rhesus monkeys, CR was
found to have significantly attenuated brain atrophy by preserv-
ing gray matter volume (Colman et al., 2009). However, whether
CR can delay the onset of neurodegeneration and the mecha-
nisms of this process currently remain unknown.
One potential mechanism that might mediate the beneficial
effects of CR on brain health is the activation of the nicotinamide
adenine dinucleotide (NAD)-dependent protein deacetylase
SIRT1 (Guarente and Picard, 2005; Bishop and Guarente, 2007;
Bordone et al., 2007; Chen andGuarente, 2007; Lavu et al., 2008).
SIRT1 was shown to at least partly mediate the beneficial effects
of CR on AD-related pathologies (Qin et al., 2006b), on inflam-
matory responses following neurotoxic insults (Chen et al.,
2008), and on enhancing learning andmemory capacities (Fusco
et al., 2012). Moreover, SIRT1 overexpression or activation in
parallel to CR has been shown to reduce amyloid- deposition
(Chen et al., 2005; Donmez et al., 2010), tau phosphorylation
(Min et al., 2010), and microglia and neurotoxicity-dependent
inflammation (Chen et al., 2005; 2008), and to improve learning,
memory, and synaptic plasticity (Gao et al., 2010; Micha´n et al.,
2010). Furthermore, SIRT1 activation reduced axonal degenera-
tion in the Wallerian degeneration mouse model (Araki et al.,
2004) and protected against neuronal loss in mouse models of
AD and amyotrophic lateral sclerosis (Kim et al., 2007). How-
ever, the potentially beneficial implication of SIRT1 activation
following CR against neurodegeneration has not been investi-
gated.
For this study, we hypothesized that CR delays the onset of
neurodegeneration and neurodegeneration-associated patholo-
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gies such as brain atrophy, loss of synaptic plasticity, and cogni-
tive deficits via the activation of SIRT1. Furthermore, we
reasoned that if this was the case, SIRT1-activating compounds
(STACs) should be able to recapitulate the beneficial effects of
CR and provide a pharmacological alternative to this dietary
regimen.
Materials andMethods
Animals. Adult (3-month-old) double-transgenic CK-p25 mice of either
sex (Cruz et al., 2003, 2006) and their single-transgenic or nontransgenic
littermates were used for all experiments. All animal work was approved
by the Committee for Animal Care of the Division of ComparativeMed-
icine at the Massachusetts Institute of Technology.
Experimental manipulations. CR treatment on CK-p25 mice consisted
of 30%CR, representing 70% of the normal ad libitum caloric consump-
tion. Mice were first accustomed to this diet during a 6 week period and
then maintained on it for another 6 weeks, for a total duration of 3
months CR. During the last half of this treatment, p25 was induced by
doxycycline removal from the diet. Control treatment consisted of ad
libitum feeding of age- and sex-matched CK-p25 mice during the same
time. Ad libitum feeding allowed for unrestricted continuous access to
solid food andwater. In total, the CR regimenwas repeated two indepen-
dent times.
Treatment of CK-p25mice with SRT3657 tert-butyl 4-((2-(2-(6-(2-(tert-
butoxycarbonyl(methyl)amino)ethylamino)-2-butylpyrimidine-4- carbox-
amido)phenyl)thiazolo5,4-bpyridin-6-yl)methoxy)piperidine-1-carboxylate
[Sirtris-GSK; compound 10 in the study byDai et al. (2010)]was performed
by daily oral gavage with 30 mg/kg SRT3657 for 6 weeks. SRT3657 was
diluted in Vitamin E TPGS (D--tocopheryl polyethylene glycol 1000 succi-
nate; Cognis) as vehicle. Control treatment consisted of daily oral gavage
with vehicle alone. Injection volume was 0.1 ml per animal. At this formu-
lation, the brain/plasma ratio of SRT3657 at 3 mg/kg was 0.13.
Behavior. Behavioral experiments were essentially conducted as de-
scribed previously (Fischer et al., 2005; Gao et al., 2010). Open-field
behavior was monitored using the VersaMax system (Accuscan) during
20 min. For fear conditioning, mice were put in the conditioning cham-
ber (TSE Systems) for 3 min, after which a constant tone was played
during 30 s, the last 2 s of whichwere pairedwith a one-time 2 s footshock
(0.8mA). Animals were then left in the box for another 30 s. Twenty-four
hours later, mice were first tested for their contextual fear memory by
putting them into the same training chamber for 3 min, during which
their freezing behavior was scored. For assessing their cued fearmemory,
which took place at least 4 h after the contextual memory task, mice were
put into a visually (gray instead of transparent) and contextually (flat
instead of gridded surface) different box with a different smell (vanilla
scented instead of ethanol scented) for a total of 3 min, the first half of
which no tone was played, which was taken to measure baseline freezing
levels, and the second half of which the same tone as during training was
played, which served tomeasure their cuedmemory performance. Freez-
ing was scored manually by an experimenter blind to the treatment
group, bymeasuring freezing as the absence ofmovement except briefing
every 10 s for 2 s. For the novel object recognition test, mice were habit-
uated to the open testing arena (41.3 41.3 30.5 cm) over 2 d, for four
trials per day, lasting 5 min each. During training, mice were exposed to
two unknown objects that they were allowed to explore during four
sessions of 5 min each. The objects had previously been put into a dirty
cage to avoid olfactory preferences. Object memory was tested 24 h later
by replacing one of the objects with a novel one and measuring the time
with which the animals explored the novel object during a 10min explo-
ration session. The location of the object was counterbalanced between
mice. Object exploration was scored by an automated software (Ethovision
XT) and expressed as a discrimination ratio, DR (tnovel tfamiliar1)/ttotal
with tnovel and tfamiliar being the time spent with the novel and the
familiar objects, respectively, and ttotal being the total time spent with
both objects.
Electrophysiology. Mice were killed by cervical dislocation, and the
brains were rapidly removed and transferred to ice-cold artificial CSF
(ACSF) equilibrated with 95% O2/5% CO2. Transverse hippocampal
slices (400 m thick) were cut with a Leica VT1000S vibratome and
recovered in a holding chamber at 32–34°C for 30 min, and were then
allowed to return to room temperature for at least another 60min before
recording. The ACSF used for cutting contained the following (in mM):
75 sucrose, 87 NaCl, 2.5 KCL, 1.25 NaH2PO4, 21.4 NaHCO3, 0.5 CaCl2,
7 MgCl2, 1.3 ascorbic acid, and 20 D-glucose. The same ACSF was used
for both incubation and recording, and contained the following (inmM):
119NaCl, 2.5 KCl, 2.5 CaCl2, 1NaH2PO4, 1.3MgSO4 26.2NaHCO3, and
11 D-glucose, saturated with 95% O2/5% CO2, pH 7.4. For extracellular
recordings in the CA1 region of the hippocampus, a bipolar platinum–
iridium stimulating electrode was placed in the Schaffer collateral axons
to elicit field population responses. The field EPSPs (fEPSPs) were re-
corded via a glass micropipette filled with ACSF (1–3 M) placed in the
stratum radiatum region of the CA1. Stimuli (0.1 ms duration) were
delivered every 30 s. Data were acquired using a HEKA EPC 10 amplifier
and analyzed by Patchmaster software (HEKA). Peak stimulation-
induced fEPSP amplitudes were required to be at least 0.7 mV, and stim-
ulus intensity was set to produce 30–50% of the maximal response.
Responses were allowed to stabilize, then a baseline was recorded for 30
min. Long-term potentiation (LTP) was induced by theta-burst stimula-
tion (TBS), which was delivered as four trains of four pulses at 100 Hz
separated by 200 ms. Recordings were made at baseline test intensity for
an additional hour after LTP induction. In all experiments, the initial
slope of the fEPSP was measured, and LTP for each time point was
expressed as a percentage of the preinduction baseline. For analysis,mea-
surements of evoked responses during the last 10 min of the recording
session were compared with the last 5 min of the baseline period using
Student’s t tests.
Immunohistochemistry. For immunohistochemistry, mice were per-
fused with 10% paraformaldehyde under deep anesthesia (ketamine, xy-
lazine) and their brains sectioned at 40 m thickness using a vibratome
(Leica). Slices were permeabilized with 0.1% Triton X-100, blocked, and
incubated overnight with 0.1% Triton X-100/10% fetal bovine serum in
PBS containing primary antibodies: NeuN (Millipore), GFP (Aves Labs),
synaptophysin (SVP; Sigma), SIRT1 (Abcam), SIRT3 (Santa Cruz Bio-
technology), and histone 3 lysine 56 acetylation (AcH3K56; Epitomics).
Primary antibodies were visualized with Alexa-Fluor 488, Cy3, and Cy5
antibodies (Invitrogen) in 1 PBS, and neuronal nuclei with Hoechst
33342 (Invitrogen). Note that the specificity of the SIRT1 antibody was
confirmed in SIRT1F/F animals (Cheng et al., 2003) (data not shown).
Slices were covered with Fluoromount G (Electron Microscopy Sci-
ences). Images were acquired using a confocal microscope (LSM 510;
Zeiss) and analyzed using ImageJ 1.42q. Three or four animals per group
were used.
Electron microscopy. Animals were perfused with 2.5% glutaralde-
hyde/2% paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.4.
The hippocampus was dissected out, sliced into 1 mm slices, washed in
0.1M cacodylate buffer, and postfixedwith 1%osmiumtetroxide (OsO4)/
1.5% potassiumferrocyanide (KFeCN6) for 1 h, washed in water three
times, and incubated in 1% aqueous uranyl acetate for 1 h followed by
twowashes in water and subsequent dehydration in grades of alcohol (10
min each at 50, 70, and 90%; two times for 10min at 100%). The samples
were then placed in propyleneoxide for 1 h and subsequently infiltrated
overnight in a 1:1 mixture of propyleneoxide and TAAB Epon (Marivac
Canada). The following day, the samples were embedded in TAAB Epon
and polymerized at 60 nm for 48 h. Ultrathin sections (about 60 nm)
were cut on a Reichert Ultracut-S microtome, placed onto copper grids,
stained with uranyl acetate and lead citrate and examined in a TecnaiG2
Spirit BioTWIN. Images were recorded with an AMT 2k CCD camera.
Fifteen distinct apical regions (stratum radiatum) of CA1,50–100 M
from the cell body layer of the hippocampus were imaged per animal. A
synapse was defined as an electron dense postsynaptic density area jux-
taposed to a presynaptic terminal filled with synaptic vesicles. The num-
ber of synapses was determined by an experimenter blind to treatment
and genotype.
Golgi staining. Mice were perfused with 10% paraformaldehyde, and
their entire brains Golgi-Cox stained using the Rapid Golgistain Kit (FD
NeuroTechnologies) as per the manufacturer’s instructions. Brains were
cut at 60mthickness using a Leica vibratome. The number of apical and
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basal spines on hippocampal CA1 pyramidal neurons was counted by an
experimenter blind to treatment group and genotype. Only mature
spines with a clear mushroom-like body and a distinctive shaft were
included. For each experimental group, aminimumof 10 cells from three
or four animals each was analyzed.
Immunoprecipitation andWestern blot. Immunoprecipitation (IP) was
performed by homogenizing whole-tissue hippocampal lysates in 500l
of sterile-filtered 50 mM Tris, 120 mMNaCl, and 0.5%NP-40 containing
proteinase inhibitors (Roche), followed by 15 min centrifugation at
14,000 rpm at 4°C and collection of the supernatant, which was incu-
bated 60–90minwith 1–2g of p53 (Cell Signaling Technologies). After
incubation, BSA-precleared protein G beads (GE Healthcare) were
added for 45 min at 4°C, and the immune complexes were collected at
8000 rpm for 3min, by onewash each in high-salt homogenization buffer
(containing 50 mM Tris, 500 mM NaCl, and 1% NP-40) and regular
homogenization buffer (see above). For Western blot (WB), whole-
tissue lysates were homogenized in 400 l 1
RIPA buffer containing proteinase inhibitors
(Roche). IP orWB samples were loaded on 10–
12% SDS gels, transferred onto PVDF mem-
branes, and incubated with primary antibodies
against acetylated lysine, p53 (Cell Signaling
Technologies), IgG, synaptophysin (Sigma), or
SIRT1 (Millipore) in 1 TBST, and visualized
with HRP-conjugated secondary antibodies
(GE Healthcare) and Western Lightning ECL
solutions (PerkinElmer). Band intensities were
quantified using ImageJ 1.42q.
SIRT1 activity assay. SIRT1 activitywasmea-
sured by a Fluor-de-Lys enzymatic assay (Enzo
Life Sciences) with the following specifications.
In vitro, 1.5 l of the Fluor-de-Lys substrate
was incubated with 1 l of recombinant hu-
man SIRT1protein in 30l 1 assay buffer (50
mM Tris-Cl, pH8.0, 1 mM DTT, 137 mM NaCl,
2.7 mMKCl, 4mMMgCl2, 0.1 mM EDTA, 1mM
NAD, and 10% glycerol in ddH2O) in the
presence or absence of 1 l 50 mM nicotin-
amide or 1 l 0.5 g/100 l suramin sodium.
Fluorescence was measured in transparent
polystyrol plates (Corning) by excitationwave-
length 355 nm and emission wavelength 460
nm using an infinite 200Pro microplate reader
(Tecan). In vivo, the protein content of whole-
tissue lysates was extracted as described under
immunoprecipitation (see above) and incu-
bated overnight with 1–2g of SIRT1 antibody
(Millipore). After incubation, BSA-precleared
protein A beads (GE Healthcare) were added
for 45 min at 4°C, and the immune complexes
were collected by centrifugation at 8000 rpm
for 3 min and washed twice with high-salt ho-
mogenization buffer (see Immunoprecipita-
tion and Western blot, above). The immune
complexes were then redissolved in 30 l 1
assay buffer together with 1.5 l of the Fluor-
de-Lys substrate for 30 min at 37° shaking, and
the supernatant was used for the fluorescent
measurement. SIRT1 activity was normalized
to SIRT1 protein levels.
Statistics. Statistical analyseswere performed
using GraphPad Prism 5. One-way ANOVAs
followed by Tukey’s post hoc analyses or one-
tailed Student’s t tests were used. All data are
represented as mean	 SEM. Statistical signif-
icance was set at p 0.05.
Results
CR rescues against neuronal loss and
brain atrophy
To examine whether CR can protect against neuronal loss, we
used the CK-p25 mouse model of neurodegeneration (Cruz et
al., 2003, 2006; Fischer et al., 2005). These mice allow for a time-
controlled onset of neurodegeneration in the forebrain by
doxycycline-mediated inducible activation of the CdK5 coactiva-
tor p25 (coupled to GFP) under the CamKII promoter. At 6
weeks of p25 induction, these mice display substantial neuro-
nal loss, reduced dendritic arborization, reduced synaptic
density and plasticity, as well as learning and memory deficits.
CK-p25 mice were subjected to 3 months of 30% calorie re-
striction (CK-p25,CR) (Fig. 1A), the typical regimen of food
reduction found to increase rodent lifespan (Bishop and
Guarente, 2007). After 6 weeks of CR, when the animals’ re-
Figure 1. A regimen of 3month 30% CR reduces neurodegeneration. A, Schematic of the experimental timeline. Three groups
ofmicewere used: CON,AL, CK-p25,AL, and CK-p25,CR.B, Weight development over the experimental timeline of all three groups
ofmice used in this study. C, CR-mediated preservation of neuronal integrity in CK-p25,CR animals. Immunohistochemical images
depicting the number of neurons as evidenced by NeuN-staining and the number of p25-expressing cells by GFP-staining. Scale
bars, 200m. D, Quantification of NeuN-positive cells under C. One-way ANOVA (F(2,9) 10.01, p 0.01), followed by Tukey’s
post hoc tests; n 4 mice each. E, Quantification of GFP-positive cells under C (one-tailed t test, t(4) 3.56; n 3 each). F,
CR-mediated preservation of overall brainmass. One-way ANOVA F(2,30) 102.6, p 0.0001, followed by Tukey’s post hoc tests;
n 12 for CON,AL and CK-p25,AL; n 9 for CK-p25,CR. *p 0.05; **p 0.01; ***p 0.001 for Tukey’s post hoc comparisons.
All values are mean	 SEM.
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duction in body weight reached asymp-
totic levels (Fig. 1B), we induced
transgene production by removing
doxycycline from the diet (Fig. 1A). CK-
p25,CR animals were compared to CK-
p25 mice fed ad libitum (CK-p25,AL)
and to control mice fed ad libitum
(CON,AL) (see Materials and Methods)
(Fig. 1A,B).
Following the regimen of CR, we
found that CK-p25,CR animals had a sim-
ilar number of neurons in hippocampus
area CA1 compared to CON,AL animals
as evidenced by NeuN immunohisto-
chemistry, despite the profound neuronal
loss displayed byCK-p25,AL animals (Fig.
1C,D) (Fischer et al., 2007). The number
of neurons in CK-p25,CR animals was
significantly higher than in CK-p25,AL
animals (Fig. 1C,D), an effect that was also
detectable by measuring the amount of
GFP-positive p25-expressing cells in
this brain area (Fig. 1E). This suggests
that CR not only rescues against neuro-
nal death in p25-positive neurons, but
in a non cell-autonomous way through-
out this brain area. These neuroprotective
effects of CR were also observed by an
attenuated loss of brain mass in CK-
p25,CR animals compared to CK-p25,AL
mice (Fig. 1F). Therefore, a regimen of
30% CR effectively rescued against p25-
driven neurodegeneration.
CR preserves synaptic density
To assess whether CR also preserves struc-
tural synaptic integrity in CK-p25 mice, we
measured synaptic density by immunohis-
tochemical labelingofSVP,amarkerofpre-
synaptic terminals. SVP labeling was
markedly reduced in the stratum radiatum
of CK-p25,AL animals compared to
CON,AL mice (Fig. 2A,B) (Fischer et al.,
2007). In contrast, in CR-treated CK-p25
mice the levels of SVP were comparable to CON,AL mice, and sig-
nificantly elevated over those in CK-p25,AL animals (Fig. 2A,B).
Similar results were obtained byWestern blot analysis of SVP levels
(data not shown). Thus, CR rescued against the loss of presynaptic
terminals.
Next, tomore precisely determine the effect of CR on synaptic
integrity, we examined the number of functional synapses by
transmission electron microscopy. We defined a synapse as an
electron-rich postsynaptic density area juxtaposed to a presynap-
tic terminal filled with synaptic vesicles (see Materials andMeth-
ods). We found that in the stratum radiatum of CK-p25,CR
animals, the number of functional synapses was markedly ele-
vated over CK-p25,AL mice, and not significantly different from
that in CON,AL animals (Fig. 2C,D). In addition to preserving
presynaptic terminals, CR was thus also effective to prevent the
loss of functional synapses that normally occurs during p25-
mediated neurodegeneration (Fischer et al., 2005).
Another aspect of synaptic integrity is the number of dendritic
spines, which reflects the degree of connectivity between neurons
and thereby synaptic strength (Fiala et al., 2002). To explore
whether CR affects dendritic spine density, we used Golgi im-
pregnation of CA1 pyramidal neurons. We found that whereas
CK-p25,AL mice had lower spine density than their control lit-
termates (CON,AL), CK-p25mice that underwent CR had a sim-
ilar number of spines per given length to CON,AL animals, a
number that was significantly higher when compared to CK-
p25,AL mice (Fig. 2E,F). Together, these data indicate that, in
addition to rescuing against neurodegeneration, CR is also effec-
tive in maintaining synaptic density.
CR preserves synaptic plasticity andmemory capacities
As structural synaptic integrity was rescued by the CR regimen,
we next questioned if such beneficial effects would also translate
into ameliorated synaptic plasticity and enhanced memory ca-
pacities. Six-week induced CK-p25 mice show impairments in
hippocampal LTP and associative and spatial memory tasks (Fi-
scher et al., 2005). We therefore asked whether CR had a positive
effect on LTP and these types of memory. We first measured
Figure 2. CR protects structural synaptic and dendritic integrity. A, CR-mediated preservation of presynaptic terminals in
CK-p25,CR animals as evidenced by SVP immunohistochemistry in the stratum radiatum of hippocampal area CA1. B, Quantifica-
tion ofA [one-way ANOVA (F(2,8) 8.99, p 0.01) followed by Tukey’s post hoc tests; n 3 for CON,AL and CK-p25,CR; n 5 for
CK-p25,AL]. C, CR-mediated preservation of the number of synapses in the hippocampus of CK-p25,CR animals as evidenced by
transmission electronmicroscopy.D, Quantification of C.One-way ANOVA (F(2, 6) 24.84, p 0.01) followed by Tukey’s post hoc
tests; n 3 mice each. E, CR-mediated preservation of the number of spines per given dendritic length in the hippocampus of
CK-p25,CR animals as evidenced by Golgi impregnation. F, Quantification of E [one-way ANOVA (F(2,22) 23.31, p 0.01)
followed by Tukey’s post hoc tests; n 7–10 dendrites per animal, 3 animals each]. *p 0.05; **p 0.01; ***p 0.001 for
Tukey’s post hoc comparisons. All values are mean	 SEM. Scale bars: A, 100m; C, 0.5m; E, 2m.
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fEPSPs following theta-burst stimulation of Schaffer collaterals.
While this stimulation was not capable of evoking LTP in CK-
p25,AL animals, it did so inCK-p25,CR animals to the extent that
fEPSPs of CK-p25,CR mice were undistinguishable from
CON,AL animals (Fig. 3A). Importantly, basal synaptic transmis-
sion as measured by the synaptic input–output relationship was
similar between all three groups, albeit slightly reduced in CK-
p25,AL and CK-p25,CR animals (Fig. 3B). Thus, CR rescued
against neurodegeneration-mediated synaptic plasticity deficits.
Then, we measured the animals’ memory performance on a
cued and contextual version of fear conditioning andon anobject
recognition paradigm to assess associative
and spatial memories for objects, respec-
tively. On the cued fear conditioning task,
CK-p25,CR animals remembered the
tone significantly better than CK-p25,AL
animals 24 h after training, at levels indis-
tinguishable from those of CON,AL ani-
mals (Fig. 3C, After). Importantly, the fear
response of CK-p25,CR mice upon reex-
posure to the conditioning chamber
alone, i.e., before the onset of the tone,
was comparable between all three groups
(Fig. 3C, Before), suggesting a selective
enhancement of the trained memory, and
not an overall increase of the fear reaction.
A similar rescue in memory performance
was observed in the contextual fear condi-
tioning paradigm 24 h after training: CK-
p25,CR animals performed significantly
better than CK-p25,AL mice, at levels
comparable to CON,AL animals (Fig.
3D). Last, on the novel object recognition
task, CK-p25,AL mice spent significantly
less time exploring the novel object than
CON,ALmice 24 h after training, indicat-
ing impaired object memory (Fig. 3E).
CK-p25,CR mice, however, spent signifi-
cantly more time with the novel object
than CK-p25,AL mice, at levels indistin-
guishable from CON,AL animals (Fig.
3E), suggesting that CR was capable of
preserving object memory. There was no
difference in object preference during
training (data not shown).
Importantly, CR treatment per se did
not alter overall locomotor activity as as-
sessed by total distance moved and time
spent moving in an open-field test, and
CRdid further not affect the animals’ anx-
iety as measured by the time spent in the
center of an open arena, nor their ex-
ploratory behavior, indicated by their
time spent rearing (data not shown).
Therefore, without affecting the ani-
mals’ general behavior, the regimen of
CR specifically improved synaptic plas-
ticity as well as associative and object
recognition memories.
CRactivatesSIRT1andSIRT1-mediated
neuroprotective mechanisms
One potential mechanism that might me-
diate the beneficial effects of CR against neurodegeneration and
its associated structural and behavioral impairments involves the
activation of SIRT1, since SIRT1 overexpressing mice were
shown to recapitulate the majority of the systemic effects of CR
(Bordone et al., 2007), and because SIRT1 expression was found
to be increased in the brains of CR-treated animals (Qin et al.,
2006b; Chen et al., 2008). Based on this, we first measured the
levels of hippocampal SIRT1 by immunohistochemistry. In
agreement with previous reports (Qin et al., 2006b; Chen et al.,
2008), we found SIRT1 protein expression to be markedly in-
creased in this brain area in CK-p25,CR animals compared to
Figure 3. CR maintains synaptic plasticity and memory. A, Preservation of long-term potentiation by CR. fEPSPs (expressed in
percentage of maximal amplitude) in hippocampal area CA1 of CON,AL, CK-p25,AL and CK-p25,CR animals (n 3–4 slices from
3–4mice each) before andafter TBS. *p0.05byANOVA for the effect of treatment. Sample traces above the line chart represent
fEPSPs at 1 min before (black) and 1 h after (colored) TBS. B, Input– output relationship of comparable baseline synaptic trans-
mission between CON,AL, CK-p25,AL, and CK-p25,CR animals. C, Cued fear conditioning. Left, Freezing responses before the onset
of the tone were comparable between CON,AL, CK-p25,AL and CK-p25,CR animals 24 h after training. Right, Freezing responses
after the onset of the tone show comparablememory retention between CON,AL and CK-p25,CR animals, but reducedmemory for
CK-p25,AL mice. One-way ANOVA (F(2,30)  6.29, p 0.01) followed by Tukey’s post hoc tests; n 10–12 mice each. D,
Contextual fear conditioning. Freezing responses 24 h after training on a contextual fear conditioning task show comparable
memory retention between CON,AL and CK-p25,CR animals, but reducedmemory for CK-p25,ALmice [one-way ANOVA (F(2,30)
7.52, p 0.01) followed by Tukey’s post hoc tests; n 10–13mice each]. E, Novel object recognition. Discrimination ratio 24 h
after training revealing a significantly enhanced object memory in CK-p25,CR compared to CK-p25,AL animals [one-way ANOVA
(F(2,19) 7.16, p 0.01) followed by Tukey’s post hoc tests; n 7–8 mice each]. *p 0.05; **p 0.01 for Tukey’s post hoc
comparisons. All values are mean	 SEM.
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CK-p25,AL mice (Fig. 4A,B). Concomi-
tant to the increase of SIRT1, we observed
a significant reduction in acetylation of
H3K56, a target of SIRT1’s deacetylase ac-
tivity (Kong et al., 2011), in CK-p25,CR
compared to CK-p25,AL mice (Fig.
4C,D). As SIRT1 levels in CK-p25 animals
have been found previously to be elevated
over those in control animals, and as this
upregulation confers protection against
neurotoxicity (Kim et al., 2007), CR is
likely to further potentiate the neuropro-
tective effects of SIRT1. In contrast, the
levels of SIRT3, a sirtuin with antioxidant
characteristics that is also known to be re-
sponsive to CR (Someya et al., 2010), re-
mained unchanged (data not shown).
Next, we measured the activity of
SIRT1 in CK-p25,CR and CK-p25,AL an-
imals. We immunoprecipitated SIRT1
out of hippocampal lysates and then fluo-
rometrically assessed its enzymatic activ-
ity (seeMaterials andMethods). To assure
that this method does indeed measure the
deacetylase activity of SIRT1, we first per-
formed an in vitro test reaction, in which
we combined recombinant SIRT1 to-
gether with a deacetylase substrate and the
known SIRT1-specific inhibitors nicotin-
amide or suramin sodium. The fluoro-
metric assay reflected a complete in vitro
inhibition of recombinant SIRT1 activ-
ity [recombinant SIRT1 plus substrate,
42426 fluorescent activity in arbitrary
units (f.a.a.u.); recombinant SIRT1 plus
substrate plus nicotinamide, 7327 f.a.a.u.;
recombinant SIRT1 plus substrate plus
suramin sodium, 7547 f.a.a.u.; substrate
alone, 4649 f.a.a.u.]. Using this assay in
vivo, we observed that CR significantly in-
creased the activity of SIRT1 in CK-
p25,CR compared to CK-p25,AL animals
(Fig. 4E). Therefore, the CR regimen in
CK-p25 mice not only increased SIRT1
protein levels, but also its activity.
One of the downstream mechanisms
by which SIRT1 increases cellular lifespan
is p53 (Chen and Guarente, 2007), a proapoptotic transcription
factor that promotes cellular senescence (Oren, 2003). Upon
SIRT1-mediated deacetylation, p53 becomes inactivated (Luo et
al., 2001; Vaziri et al., 2001). Based on this knowledge, we mea-
sured p53 acetylation in hippocampal extracts of CK-p25 ani-
mals following CR or AL treatment by immunoprecipitation
of p53 coupled to Western blot analysis. We observed that the
acetylation of p53 was significantly reduced following CR
treatment (Fig. 4F), suggesting that p53 becomes inactivated
following CR. Together, these results indicate that CR upregu-
lates SIRT1 and activates its deacetylase function, which co-
occurs with a deacetylation of p53 and likely p53 inactivation.
As a reduction of p53 has been shown to be neuroprotective
(Kim et al., 2007), this SIRT1-p53 pathway constitutes a po-
tential mechanism by which CR might rescue against neuro-
degeneration.
SRT3657, a small-molecule activator of SIRT1
Since SIRT1 expression and activity were increased by CR, we
reasoned that by using small-molecule STACswemight be able to
obtain the same beneficial effects against neurodegeneration as
under the CR regimen. To test this, we administered a STAC to
CK-p25mice during the 6 weeks of p25 transgene induction (Fig.
5A). This timeline was chosen to most closely recapitulate the
asymptotic phase of CR during p25-transgene induction (Fig.
1B). CK-p25 mice were given a known SIRT1-specific STAC,
SRT3657 (CK-p25,SRT3657) (Dai et al., 2010) by oral gavage, or
its vehicle alone (CK-p25,VEH) (Fig. 5A). As shown in Figure 5B,
SRT3657 treatment significantly upregulated the activity of
SIRT1 in hippocampal extracts of CK-p25 animals. Such in-
creased SIRT1 activity was also reflected by decreased H3K56
acetylation (Fig. 5C,D). Thus, SRT3657 treatment effectively ac-
tivated SIRT1 in vivo.
Figure4. SIRT1 activationby the CR regimen.A, Increased SIRT1 expression following CR in hippocampal area CA1as evidenced
bySIRT1 immunohistochemistry.B, QuantificationofA (one-tailed t test, t(4)2.68;n3each).C, DecreasedAcH3K56 following
CR in hippocampal area CA1 as evidenced byAcH3K56 immunohistochemistry.D, Quantification of C (one-tailed t test, t(4) 3.84;
n 3 each). E, Increased SIRT1 deacetylase activity following CR. SIRT1 deacetylase activity in CK-p25,AL and CK-p25,CR hip-
pocampi. One-tailed t test, t(5) 2.03; n 3 for CK-p25,AL; n 4 for CK-p25,CR. F, Decreased acetylation of p53 following CR.
Left, Representative images of Western blot analysis following immunoprecipitation of acetylated (top) and total (bottom) p53
levels in CK-p25,AL and CK-p25,CR hippocampi. Right, Quantification of the ratio of acetylated/total p53 protein levels (one-tailed
t test, t(13)2.04;n6 for CK-p25,AL;n9 for CK-p25,CR). *p0.05; **p0.01 for one-tailed t tests. All values aremean	
SEM. Scale bars: 100m.
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If a STAC is to recapitulate CR in vivo, it should activate SIRT1
downstreammechanisms similar to theCR treatment. Therefore,
we next tested whether the acetylation of the proapoptotic pro-
tein p53 might be altered by SRT3657 treatment. Similar to the
CR regimen, we found the acetylation of p53 to be significantly
reduced in the hippocampus of CK-p25,SRT3657 mice com-
pared to CK-p25,VEH animals (Fig. 5E). This suggests that sim-
ilar neuroprotective pathwaysmight be activated by the SRT3657
treatment.
SRT3657 recapitulates the neuroprotective potential of CR
To further assess a potential neuroprotective role of SRT3657,
we examined synaptic density by SVP immunohistochemistry.
Compared to CK-p25,VEH animals, CK-p25,SRT3657 mice
displayed higher synaptic density in the
stratum radiatum of the hippocampus
at levels indistinguishable from CON,
VEH animals (Fig. 6A,B), indicating pre-
served synaptic integrity. Then, to account
for the extent of neurodegeneration, we ex-
amined the number of neurons by NeuN-
immunohistochemistry in hippocampal
area CA1. We found that the number of
NeuN-positive cells was significantly in-
creased in CK-p25,SRT3657 animals com-
pared to CK-p25,VEH mice, to a number
comparable to CON,VEH animals (Fig.
6C,D), demonstrating that neurodegenera-
tion canbe at least partially preventedby the
STAC SRT3657. Intriguingly, this was fur-
ther evidenced by a partial rescue in overall
brain loss (Fig. 6E), similar to the effect ob-
served under the CR regimen (Fig. 1F).
Last, to evaluate whether the so-main-
tained neuronal and synaptic integrity
might translate into behavioral improve-
ments, we tested CK-p25,SRT3657 and
control littermates for fear memory.
Twenty-four hours after training, CK-
p25,SRT3657 mice froze significantly more
than CK-p25,VEH mice on the cued fear
conditioning task after the onset of the tone,
but not before (Fig. 6F), indicating en-
hanced memory retention. Likewise, CK-
p25,SRT3657 mice outperformed their
VEH-treated counterparts on the contex-
tual fear memory test (Fig. 6G). Impor-
tantly, both cued and contextual fear
memory retention were comparable be-
tween CK-p25,SRT3657 and CON,VEH
animals. Furthermore, SRT3657 treatment
per se did not affect overall locomotor and
exploratory activity, nor did it alter the ani-
mals’ anxiety levels (data not shown). To-
gether, these data indicate that SRT3657
treatment prevented synaptic and neuronal
loss andeffectively rescuedagainstneurode-
generation-driven memory impairments.
For that reason, SRT3657 treatment might
constitute a pharmacological alternative
to CR.
Discussion
In the current study, we have shown
that a regimen of CR effectively delays the onset of neurode-
generation, preserves structural and functional synaptic
plasticity as well as memory capacities, and activates the
expression and activity of SIRT1, a known promoter of neu-
ronal lifespan (Tang, 2009; Zhang et al., 2011). Importantly,
mimicking the dietary regimen by oral administration of the
STAC SRT3657 recapitulated the beneficial effects of CR
against neurodegeneration-associated pathologies and thus
might constitute a pharmacological alternative to CR against
neurodegeneration.
Expanding the favorable effects of CR on memory perfor-
mance (Halagappa et al., 2007; Fonta´n-Lozano et al., 2008;Wu et
al., 2008a; Witte et al., 2009) and against AD-related pathologies
Figure 5. SRT3657 activates SIRT1 in CK-p25 mice. A, Schematic of the experimental timeline. Two groups of mice were
used: CK-p25,VEH and CK-p25,SRT3657. B, Increased SIRT1 activity following SRT3657 treatment. SIRT1 deacetylase
activity in CK-p25,VEH and CK-p25,SRT3657 hippocampi (one-tailed t test, t(8) 2.65; n 4 for CK-p25,VEH; n 6 for
CK-p25,SRT3657). C, Decreased AcH3K56 following SRT3657 treatment in hippocampal area CA1 as evidenced by AcH3K56
immunohistochemistry. Scale bar, 100m.D, Quantification of C. One-tailed t test, t(8) 2.61; n 4 for CK-p25,VEH; n
6 for CK-p25,SRT3657. E, Decreased acetylation of p53 following SRT3657 treatment. Top, Representative images of
Western blot analysis following immunoprecipitation of acetylated (top) and total (bottom) p53 levels in CK-p25,VEH
and CK-p25,SRT3657 hippocampi. Bottom, Quantification of the ratio of acetylated/total p53 protein levels (one-tailed t
test, t(8)  2.61; n  4 for CK-p25,VEH; n  6 for CK-p25,SRT3657). *p  0.05 for one-tailed t tests. All values are
mean	 SEM.
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such as amyloid- accumulation (Patel et
al., 2005; Wang et al., 2005; Qin et al.,
2006a,b; Halagappa et al., 2007; Wu et al.,
2008b; Mouton et al., 2009) and tau hy-
perphosphorylation (Halagappa et al.,
2007), this study newly shows that a regi-
men of CR can also delay the onset of neu-
rodegeneration per se. It thereby
complements results in rhesus monkeys,
where CR was shown to preserve gray
matter volume (Colman et al., 2009), and
in Caenorhabditis elegans, where it was
found to prevent the destruction of dopa-
minergic neurons in a Parkinson’s disease
model (Jadiya et al., 2011). One question
that remains to be answered is whether
the regimen of CR would also prove ef-
fective against neurodegeneration when
started later, i.e., after the onset of neu-
rodegeneration. Likewise, future studies
will need to assess whether the beneficial
effects of CR are permanent or whether
neurodegeneration regains the upper
hand once the regimen of CR is stopped.
Mechanistically, the CR regimen used
here was found to activate SIRT1. This is
in line with previous reports showing that
CR increases hippocampal SIRT1 expres-
sion (Qin et al., 2006b; Chen et al., 2008)
and that, conversely, a fat-rich diet re-
duces hippocampal SIRT1 expression
(Heyward et al., 2012). Although we can-
not determine that the beneficial effects
of CR are solely mediated by SIRT1, nor
that SIRT1 acts in parallel to CR, it is
nevertheless likely that such activation
of SIRT1 does contribute to the positive
effects of CR: overexpression of SIRT1
has been shown previously to not only
improve memory performance (Gao et
al., 2010; Micha´n et al., 2010), but also
to protect against neurodegeneration
(Araki et al., 2004; Kim et al., 2007),
whereas RNAi-mediated knockdown of
SIRT1 levels precluded the neuropro-
tective effects of CR in C. elegans (Jadiya
et al., 2011).
This possibility is further supported
by our findings that, using the STAC
SRT3657, the beneficial effects of CR
could be essentially recapitulated. Such
treatment represents the first direct ev-
idence of a STAC as a pharmacological
alternative to a dietary regimen against neurodegeneration.
Since dietary changes do not always produce the anticipated
beneficial outcomes (Mattison et al., 2012), STAC treatments
might be preferable over CR. While we did not observe any
adverse effects following SRT3657 treatment, more refined
studies are still needed to determine the overall safety and
tolerability of this STAC. Moreover, similar questions as
raised by the results obtained with the CR treatment concern-
ing the timing of administration as well as the persistence of
the beneficial effects are also applicable here. In addition,
it would be interesting to assess the combined effects of phar-
macological SIRT1 activation and CR on the progression of
neurodegeneration. Such experiments would also help to dis-
entangle the question as to whether SIRT1 activation acts via
the same pathway as CR.
Last, although we identified p53 deactivation as a potential
target of the SRT3657 and CR regimen, other neuroprotective
pathways such as the Forkhead box protein O transcription fac-
tors, insulin/IGF-signaling, PGC1, or NfB might also be acti-
vated following both STAC and CR treatments (Gan andMucke,
Figure 6. SRT3657 recapitulates the beneficial effects of CR. A, SRT3657-mediated increase in presynaptic terminals in
the stratum radiatum of hippocampal area CA1 in CK-p25,SRT3657 animals compared to CK-p25,VEH mice as evidenced by
SVP immunohistochemistry. B, Quantification of A [one-way ANOVA (F(2,11) 5.77, p 0.05) followed by Tukey’s post hoc
tests; n  4 –5 mice each]. C, SRT3657-mediated increase in the number of neurons in hippocampal area CA1 in CK-
p25,SRT3657 animals compared to CK-p25,VEH mice as revealed by NeuN-immunohistochemistry. D, Quantification of C
[one-way ANOVA (F(2,12)  29.99, p  0.0001) followed by Tukey’s post hoc tests; n  3– 6 mice each]. E, SRT3657-
mediated preservation of overall brain mass. One-way ANOVA (F(2,11) 19.68, p 0.001) followed by Tukey’s post hoc
tests; n 4 –7mice each. F, Cued fear conditioning. Left, Freezing responses before the onset of the tone were comparable
between CK-p25,VEH and CK-p25,SRT3657 animals 24 h after training. Right, Freezing responses after the onset of the tone
show improved memory retention in CK-p25,SRT3657 mice [one-way ANOVA (F(2,23)  7.47, p  0.01) followed by
Tukey’s post hoc tests; n 8 –10 mice each]. G, Contextual fear conditioning. Freezing responses 24 h after training on a
contextual fear conditioning task show improved memory retention in CK-p25,SRT3657 mice [one-way ANOVA (F(2,22)
5.28, p 0.05) followed by Tukey’s post hoc tests; n 8 –10mice each]. *p 0.05; **p 0.01; ***p 0.001 for Tukey’s
post hoc comparisons. All values are mean	 SEM. Scale bars: A, 50m; C, 20m.
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2008; Lavu et al., 2008). These limitations notwithstanding, the
present study proposes the STAC SRT3657 as an attractive alter-
native route to convey the beneficial effects of CR against neuro-
degeneration, without the need for CR itself.
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